Skip to main content

Advertisement

Log in

Acetyl-L-Carnitine as an Adjunctive Therapy in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Placebo-Controlled Trial

Child Psychiatry & Human Development Aims and scope Submit manuscript

Abstract

The objective of this study was to test whether a previous observed Acetyl-L-carnitine (ALC) treatment effect could be repeated in an ALC adjunctive therapy treatment trial of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. This was a six-week, randomized clinical trial undertaken in an outpatient child and adolescent clinic. Subjects included 40 outpatients (28 boys and 12 girls) between the ages of 7–13 who met the DSM-IV-TR diagnostic criteria for ADHD. All study subjects were randomly assigned to receive treatment using capsules of ALC doses ranging from 500 to 1,500 mg/day depending on the weight of the child plus methylphenidate at a dose of 20–30 mg/day depending on weight or Placebo plus methylphenidate at a dose of 20–30 mg/day depending on weight. The principal measure of outcome was the Teacher and Parent attention deficit/hyperactivity disorder Rating Scale- IV. No difference was observed between the two groups on the Parent and Teacher Rating Scale scores (df = 1; F = 0.10; P = 0.74 and df = 1; F = 0.22; P = 0.63 respectively). Side effects consisting of headache and irritability were observed more frequently in the methylphenidate plus placebo group. The results of this study do not support the application of ALC as an adjunctive therapy to methylphenidate in children and adolescents with ADHD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Noorbala AA, Akhondzadeh S (2006) Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy. Arch Iranian Med 9:374–380

    Google Scholar 

  2. Mohammadi MR, Akhondzadeh S (2007) Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. Exp Rev Neurotrapeutics 7:195–201

    Article  Google Scholar 

  3. Curatolo P, Paloscia C, D’Agati E, Moavero R, Pasini A (2009) The neurobiology of attention deficit/hyperactivity disorder. Eur J Paediatr Neurol 13:299–304

    Article  PubMed  Google Scholar 

  4. Dopheide JA, Pliszka SR (2009) Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy 29:656–679

    Article  PubMed  Google Scholar 

  5. Adriani W, Rea M, Baviera M, Invernizzi W, Carli M, Ghirardi O, Caprioli A, Laviola G (2004) Acetyl-L-carnitine reduces impulsive behaviour in adolescent rats. Psychopharmacology (Berl) 176:296–304

    Article  Google Scholar 

  6. Rebouche CJ (2004) Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann NY Acad Sci 1033:30–41

    Article  PubMed  Google Scholar 

  7. Van Oudheusden LJ, Scholte HR (2002) Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 67:33–38

    Article  PubMed  Google Scholar 

  8. Torrioli MG, Vernacotola S, Peruzzi L, Tabolacci E, Mila M, Militerni R, Musumeci S, Ramos FJ, Frontera M, Sorge G, Marzullo E, Romeo G, Vallee L, Veneselli E, Cocchi E, Garbarino E, Moscato U, Chiurazzi P, D’Iddio S, Calvani M, Neri G (2008) A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A 146:803–812

    PubMed  Google Scholar 

  9. Arnold LE, Amato A, Bozzolo H, Hollway J, Cook A, Ramadan Y, Crowl L, Zhang D, Thompson S, Testa G, Kliewer V, Wigal T, McBurnett K, Manos M (2007) Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 17:791–802

    Article  PubMed  Google Scholar 

  10. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn, text revision (DSMIV- TR). American Psychiatric Association, Washington

    Book  Google Scholar 

  11. Ghanizadeh A, Mohammadi MR, Yazdanshenas A (2006) Psychometric properties of the Farsi translation of the Kiddie schedule for affective disorders and Schizophrenia- present and lifetime version. BMC Psychiatry 15(6):10

    Article  Google Scholar 

  12. DuPaul G, Power T, Anastopoulos A, Reid R (1998) ADHD rating scale-IV. Guilford, New York

    Google Scholar 

  13. Akhondzadeh S, Tavakolian R, Davari-Ashtiani R, Arabgol F, Amini H (2003) Selegiline in the treatment of attention-deficit hyperactivity disorder in children: a double-blind and randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 27:841–845

    Article  PubMed  Google Scholar 

  14. Akhondzadeh S, Mohammadi MR, Khademi M (2004) Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. BMC Psychiatry 8(4):9

    Article  Google Scholar 

  15. Amiri S, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Kahbazi M, Akhondzadeh S (2008) Modafinil as a treatment for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 32:145–149

    Article  PubMed  Google Scholar 

  16. Kahbazi M, Ghoreishi A, Rahiminejad F, Mohammadi MR, Kamalipour A, Akhondzadeh S (2009) A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Res 168:234–237

    Article  PubMed  Google Scholar 

  17. Salehi B, Imani R, Mohammadi MR, Fallah J, Mohammadi M, Ghanizadeh A, Tasviechi AA, Vossoughi A, Rezazadeh SA, Akhondzadeh S (2010) Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 34:76–80

    Article  PubMed  Google Scholar 

  18. Zarinara AR, Mohammadi MR, Hazrati N, Tabrizi M, Rezazadeh SA, Rezaie F, Akhondzadeh S (2010) Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Hum Psychopharmacol 25:530–535

    PubMed  Google Scholar 

  19. Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A (2004) Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 13(suppl 1):102–116

    Google Scholar 

  20. Arduini A, Denisova N, Virmani A, Avrova N, Federici G, Arrigoni-Martelli E (1994) Evidence for the involvement of carnitine dependent long-chain acyltransferases in neuronal triglyceride and phospholipid fatty acid turnover. J Neurochem 62:1530–1538

    Article  PubMed  Google Scholar 

  21. Richardson AJ, Ross MA (2000) Fatty acid metabolism in neurodevelopmental disorder: a new prospective on associations between attention-deficit/hyperactivity disorder, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins Leukotr Essent Acids 63:1–9

    Article  Google Scholar 

  22. Calvani M, Arrigoni-Martelli E (1999) Attenuation by acetyl-L-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion. Int J Tissue React 21:1–6

    PubMed  Google Scholar 

Download references

Acknowledgments

This study was the post graduate thesis of Dr. Shahram Heidari toward the Iranian board of child psychiatry. This study was supported by a grant from Tehran University of Medical Sciences (Grant No: 8642) to Prof. Shahin Akhondzadeh.

Conflict of interest

All authors declare no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shahin Akhondzadeh.

Additional information

Trial Registration: clinicaltrials.gov identifier: NCT01099072 (Clinical Trials http://www.clinicaltrials.gov/).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abbasi, SH., Heidari, S., Mohammadi, MR. et al. Acetyl-L-Carnitine as an Adjunctive Therapy in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Placebo-Controlled Trial. Child Psychiatry Hum Dev 42, 367–375 (2011). https://doi.org/10.1007/s10578-011-0220-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10578-011-0220-y

Keywords

Navigation